SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial

Article English OPEN
Crabb, Simon; Danson, Sarah J.; Catto, James W. F.; McDowell, Cathy; Lowder, James N.; Caddy, Joshua; Dunkley, Denise; Rajaram, Jessica; Ellis, Deborah; Hill, Stephanie; Hathorn, David; Whitehead, Amy; Kalevras, Mihalis; Huddart, Robert; Griffiths, Gareth; (2018)
  • Publisher: BioMed Central
  • Journal: Trials,volume 19 (issn: 1745-6215, eissn: 1745-6215)
  • Related identifiers: doi: 10.1186/s13063-018-2586-7, pmc: PMC5883402
  • Subject: Phase I/II | R5-920 | Cisplatin resistance | Urothelial bladder cancer | Medicine (General) | DNA methyltransferase inhibitor | Randomised controlled trial | Study Protocol | Guadecitabine

Background Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer, Cancer Research UK, Acces... View more
Share - Bookmark